Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.34

Shares of Genmab A/S (NASDAQ:GMAB) gapped down before the market opened on Friday . The stock had previously closed at $29.34, but opened at $27.91. Genmab A/S shares last traded at $28.03, with a volume of 148,384 shares.

Wall Street Analyst Weigh In

Several research firms have weighed in on GMAB. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Monday. Truist Financial reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $48.50.

Genmab A/S Trading Down 4.4 %

The company has a 50 day simple moving average of $29.34 and a 200-day simple moving average of $29.92. The stock has a market cap of $18.55 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 1.08 and a beta of 1.00.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $603.30 million for the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. Equities analysts forecast that Genmab A/S will post 1.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new position in Genmab A/S during the third quarter worth approximately $27,000. Pinnacle Bancorp Inc. increased its position in Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after buying an additional 638 shares during the last quarter. Russell Investments Group Ltd. increased its position in Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares during the last quarter. GAMMA Investing LLC increased its position in Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares during the last quarter. Finally, NBC Securities Inc. acquired a new position in Genmab A/S during the third quarter worth approximately $37,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.